The main objective of this study is to evaluate the efficacy, dose-ranging and initial safety
profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 25 to 180 mcg
per dosing in comparison to a DPI Placebo Control and an Albuterol metered dose inhaler (MDI)
Active Control.
This study will be conducted in male and female adult patients who have mild-to-moderate
persistent asthma for at least 6 months, but are otherwise generally healthy.